SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing prac­tices

Fol­low­ing Bio­gen’s an­nounce­ment of minis­cule 2021 sales for its con­tro­ver­sial new Alzheimer’s drug yes­ter­day, the com­pa­ny al­so re­vealed that the Fed­er­al Trade Com­mis­sion and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER